EUVIMEDEUVIMED entdecken
Leserbrief

Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly( ADP ‐ribose) polymerase proteins inhibitors for solid tumours

Emmanuel Almanza-Huante iD, Alex Bataller iD, Samuel Urrutia, Georgina Gener-Ricos, Robert Edward Briski, Rashmi Kanagal-Shamanna iD, Karen H Lu, Shannon N Westin, Timothy A Yap, Koichi Takahashi, Farhad Ravandi, Yesid Alvarado und 4 weitere

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18766 ↗

Kurz gefasst

Leserbrief in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Emmanuel Almanza-Huante und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsNeoplasmsHumansPoly(ADP-ribose) PolymerasesPoly (ADP-Ribose) Polymerase-1

Stichwörter der Autor:innen

PARP inhibitorstherapy related myeloid neoplasmstherapy-related acute myeloid leukaemiatherapy-related myelodysplastic syndrome

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesPoly (ADP-Ribose) Polymerase-1

Autor:innen und Institutionen

  • Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA.
  • Cancer Medicine, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA.
  • Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA.
  • Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA.
  • Department of Investigational Cancer Therapeutics (Phase I Program), MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA.

ORCID-Profile: Emmanuel Almanza-Huante, Alex Bataller, Rashmi Kanagal-Shamanna, Koiji Sasaki, Guillermo Garcia-Manero

Förderung

  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Almanza-Huante, E., Bataller, A., Urrutia, S., Gener-Ricos, G., Briski, R. E., Kanagal-Shamanna, R., Lu, K. H., Westin, S. N., Yap, T. A., Takahashi, K., Ravandi, F., Alvarado, Y., Kadia, T., Sasaki, K., Kantarjian, H. M., & Garcia-Manero, G. (2023). Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly( ADP ‐ribose) polymerase proteins inhibitors for solid tumours. British Journal of Haematology. https://doi.org/10.1111/bjh.18766

Vancouver

Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, et al. Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly( ADP ‐ribose) polymerase proteins inhibitors for solid tumours. British Journal of Haematology. 2023. doi:10.1111/bjh.18766

BibTeX
@article{AlmanzaHuante2023,
  author = {Almanza-Huante, Emmanuel and Bataller, Alex and Urrutia, Samuel and Gener-Ricos, Georgina and Briski, Robert Edward and Kanagal-Shamanna, Rashmi and Lu, Karen H and Westin, Shannon N and Yap, Timothy A and Takahashi, Koichi and Ravandi, Farhad and Alvarado, Yesid and Kadia, Tapan and Sasaki, Koiji and Kantarjian, Hagop M and Garcia-Manero, Guillermo},
  title = {Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly( ADP ‐ribose) polymerase proteins inhibitors for solid tumours},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18766}
}
Kostenlos starten →